Open an account

Corvus Pharmaceuticals

CRVS · NASDAQ

$10.23+$0.58 (+6.01%)TodayMarket closed ·
Prev close $9.65

About CRVS

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. The company is headquartered in Burlingame, California and currently employs 29 full-time employees. The company went IPO on 2016-03-23. The firm is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73.

Employees
29
Headquarters
Burlingame, California
Listed
Mar 23, 2016
Sector
Health Care
Industry
Biotechnology
Website
corvuspharma.com

CRVS key statistics

Market cap
811.77M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.10M
Volume
1.07M
Open price
$9.67
High today
$10.33
Low today
$9.65
52 Week high
$26.95
52 Week low
$6.39

Corvus Pharmaceuticals (CRVS) at a glance

As of Oct 20, 2026, Corvus Pharmaceuticals (CRVS) shares are priced at $10.23, giving the company a market cap of 811.77M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.65 and $10.33. The current price is 6.0% above the day's low and 0.9% below its high.

Volume so far is 1.07M shares, in line with the average of 1.10M shares a day.

Over the past year Corvus Pharmaceuticals has ranged from $6.39 to $26.95, and now sits 19% of the way up that range.

Corvus Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.19 per share against an estimate of -$0.1619.

The average analyst price target is $33.81, 230.5% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 9 analystsAvg $33.81
Low
$27.27
Now
$10.23
High
$44.10

CRVS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 105.0% on average.

  1. Q3 FY24: reported -$0.60 per share against an estimate of -$0.1189
  2. Q4 FY24: reported -$0.18 per share against an estimate of -$0.122
  3. Q1 FY25: reported $0.21 per share against an estimate of -$0.1212
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.1426
  5. Q3 FY25: reported -$0.12 per share against an estimate of -$0.1361
  6. Q4 FY25: reported -$0.15 per share against an estimate of -$0.1319
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.1457
  8. Q2 FY26: reported -$0.19 per share against an estimate of -$0.1619

CRVS news

  • Avi Kapoor

    Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings

  • Avi Kapoor

    Crude Oil Gains 2%; D.R. Horton Earnings Top Views

  • Press releasePRNewswire

    The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

  • Vandana Singh

    Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Earnings Scheduled For May 8, 2025

  • Avi Kapoor

    Crude Oil Gains Over 1%, General Mills Shares Fall

Similar companies

Companies in the same industry as Corvus Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.